Inflammation

Genetic Diseases, Inborn

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the Fc portion of human IgG1. Rilonacept has a molecular weight of approximately 251 kDa. Rilonacept is expressed in recombinant Chinese hamster ovary (CHO) cells.</p><p>ARCALYST is supplied in single-dose vials containing a sterile, white to off-white lyophilized powder. Each vial of ARCALYST is to be reconstituted with 2.3 mL of Sterile Water for Injection, USP. A volume of up to 2 mL can be withdrawn, which is designed to deliver 160 mg for subcutaneous administration only. The resulting solution is viscous, clear, colorless to pale yellow, and essentially free from particulates. Each vial contains 220 mg rilonacept. After reconstitution, each vial contains rilonacept (80 mg/mL), glycine (10 mg/mL), histidine (46 mM), L-arginine (50 mM), polyethylene glycol 3350 (30 mg/mL), and sucrose (20 mg/mL) at a pH of 6.5. No preservatives are present.</p></section>

Arcalyst

rilonacept

rilonacept 220 MG Injection

rilonacept 220 MG Injection [Arcalyst]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Access & Reimbursement Guide 

Coverage Authorization Request 

Coverage Authorization Appeal 

Appeal Letter Guide 

Letter of Medical Necessity 

Letter of Medical Neccessity Guide

Tiering Exception Letter

Tiering Exception Letter Guide

Kinisa OneConnect Enrollment Form: Recurrent Pericarditis 

Kinisa OneConnect Enrollment Form (Spanish): Recurrent Pericarditis 

Formulary Information: Recurrent Pericarditis 

Enroll in Patient Savings Program 

Patient Assistance Program 

Other HCP Resources: Recurrent Pericarditis

About Arcalyst: Recurrent Pericarditis 

FAQs: Recurrent Pericarditis 

Kiniksa OneConnect Support Program 

Injection Training

Patient Stories 

Patient Brochure

Instructions For Use (Video): Recurrent Pericarditis 

Kinisa OneConnect Enrollment Form: CAPS & DIRA

Kinisa OneConnect Enrollment Form (Spanish): CAPS & DIRA

Quick Start Program: CAPS & DIRA

Other HCP Resources: CAPS

Other HCP Resources: DIRA

About Arcalyst: CAPS

FAQs: CAPS

About Arcalyst: DIRA

FAQs: DIRA

Instructions For Use: All Indications

Instructions For Use (Video): DIRA

Instructions For Use (Video): CAPS